These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 18046916)

  • 1. Doxazosin in the treatment of benign prostatic hypertrophy: an update.
    Wilt TJ; MacDonald R
    Clin Interv Aging; 2006; 1(4):389-401. PubMed ID: 18046916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects.
    MacDonald R; Wilt TJ; Howe RW
    BJU Int; 2004 Dec; 94(9):1263-70. PubMed ID: 15610102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Finasteride for benign prostatic hyperplasia.
    Tacklind J; Fink HA; Macdonald R; Rutks I; Wilt TJ
    Cochrane Database Syst Rev; 2010 Oct; 2010(10):CD006015. PubMed ID: 20927745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
    McConnell JD; Roehrborn CG; Bautista OM; Andriole GL; Dixon CM; Kusek JW; Lepor H; McVary KT; Nyberg LM; Clarke HS; Crawford ED; Diokno A; Foley JP; Foster HE; Jacobs SC; Kaplan SA; Kreder KJ; Lieber MM; Lucia MS; Miller GJ; Menon M; Milam DF; Ramsdell JW; Schenkman NS; Slawin KM; Smith JA;
    N Engl J Med; 2003 Dec; 349(25):2387-98. PubMed ID: 14681504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial.
    Kirby RS; Roehrborn C; Boyle P; Bartsch G; Jardin A; Cary MM; Sweeney M; Grossman EB;
    Urology; 2003 Jan; 61(1):119-26. PubMed ID: 12559281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of doxazosin, finasteride and combination therapy on nocturia in men with benign prostatic hyperplasia.
    Johnson TM; Burrows PK; Kusek JW; Nyberg LM; Tenover JL; Lepor H; Roehrborn CG;
    J Urol; 2007 Nov; 178(5):2045-50; discussion 2050-1. PubMed ID: 17869295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ultrasound image features of intravesical prostatic protrusion indicated failure of medication therapy of finasteride and doxazosin in patients with benign prostatic hyperplasia (LUTS/BPH).
    Liu Q; Zhu Y; Liu J; Qi J; Kang J
    Int Urol Nephrol; 2017 Mar; 49(3):399-404. PubMed ID: 27987130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia.
    Logan YT; Belgeri MT
    Am J Geriatr Pharmacother; 2005 Jun; 3(2):103-14. PubMed ID: 16129387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia.
    McDonald H; Hux M; Brisson M; Bernard L; Nickel JC
    Can J Urol; 2004 Aug; 11(4):2327-40. PubMed ID: 15380054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial.
    Kaplan SA; Roehrborn CG; McConnell JD; Meehan AG; Surynawanshi S; Lee JY; Rotonda J; Kusek JW; Nyberg LM;
    J Urol; 2008 Sep; 180(3):1030-2; discussion 1032-3. PubMed ID: 18639298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia.
    Andersen M; Dahlstrand C; Høye K
    Eur Urol; 2000 Oct; 38(4):400-9. PubMed ID: 11025377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo.
    Crawford ED; Wilson SS; McConnell JD; Slawin KM; Lieber MC; Smith JA; Meehan AG; Bautista OM; Noble WR; Kusek JW; Nyberg LM; Roehrborn CG;
    J Urol; 2006 Apr; 175(4):1422-6; discussion 1426-7. PubMed ID: 16516013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study.
    Lee SH; Chung BH; Kim SJ; Kim JH; Kim JC; Lee JY
    Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):320-5. PubMed ID: 21788967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Finasteride and doxazosin alone or in combination for the treatment of benign prostatic hyperplasia.
    Bhardwa J; Goldstraw M; Tzortzis S; Kirby R
    Expert Opin Pharmacother; 2007 Jun; 8(9):1337-44. PubMed ID: 17563267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is Sexual Function Better Preserved After Water Vapor Thermal Therapy or Medical Therapy for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia?
    McVary KT; Rogers T; Mahon J; Gupta NK
    J Sex Med; 2018 Dec; 15(12):1728-1738. PubMed ID: 30446471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Rahardjo D; Soebadi DM; Sugandi S; Birowo P; Djati W; Wahyudi I
    Int J Urol; 2006 Nov; 13(11):1405-9. PubMed ID: 17083392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The clinical and flowmetric results of the treatment of benign prostatic hyperplasia with doxazosin].
    Salinas Casado J; Esteban Fuertes M; Virseda Chamorro M; Ramírez Fernández JC; Salomon Moh'd S; Luengo Alpuente S; Resel Estévez L
    Arch Esp Urol; 1999 Sep; 52(7):739-48. PubMed ID: 10540764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5alpha-reductase inhibitors: what role should they play?
    Kaplan SA
    Urology; 2001 Dec; 58(6 Suppl 1):65-70; discussion 70. PubMed ID: 11750255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms.
    Jhang JF; Jiang YH; Kuo HC
    Int J Clin Pract; 2013 Dec; 67(12):1327-33. PubMed ID: 24246211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Randomized, Open-Label, Comparative Study of Efficacy and Safety of Tolterodine Combined with Tamsulosin or Doxazosin in Patients with Benign Prostatic Hyperplasia.
    Cao Y; Wang Y; Guo L; Yang X; Chen T; Niu H
    Med Sci Monit; 2016 Jun; 22():1895-902. PubMed ID: 27260129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.